{"analyses":[{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7945","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.3","upperLimit":"36.4","value":"31.1"},{"groupId":"OG001","lowerLimit":"27.2","upperLimit":"37.4","value":"32.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"description":"ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions; PR defined as a \\>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) \\* 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemetrexed + Cisplatin"},{"description":"Pemetrexed + Cisplatin\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG001","title":"Pemetrexed + Cisplatin"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Measured Progressive Disease (Up to 30.4 Months)","title":"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR])","type":"SECONDARY","unitOfMeasure":"percentage of participants"}